ALVONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ALVOW

Alvotech

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026

$5.03+0.03 (+0.60%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 50.3
Dividend yield: –

Alvotech balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	172	51	11	66	18	32	67
Cash & Short-Term Investments	172	51	11	66	18	32	67
Receivables	70	160	41	33	29	–	–
Inventory	220	128	74	71	39	–	–
Other Current Assets	47	48	32	33	15	–	–
Total Current Assets	574	455	195	231	120	–	–
Property, Plant & Equipment	356	285	237	221	79	–	–
Operating Lease Right-of-Use Assets	138	125	120	48	127	112	–
Goodwill	13	11	12	12	12	13	–
Intangible Assets	82	21	19	26	22	–	–
Deferred Tax Assets	192	298	310	209	170	–	–
Other Long-Term Assets	8.58	3.62	2.24	5.78	1.66	–	–
Total Assets	1,487	1,221	950	828	598	–	–
Accounts Payable	126	67	81	49	29	–	–
Short-Term Debt	–	–	–	20	–	–	–
Current Portion of Long-Term Debt	37	33	38	20	2.77	–	–
Current Debt	37	33	38	40	2.77	–	–
Current Portion of Leases	12	9.52	9.68	5.16	7.30	–	–
Current Income Taxes Payable	1.04	0.20	0.93	0.93	0.84	–	–
Other Current Liabilities	94	59	63	54	42	–	–
Total Current Liabilities	304	193	261	167	112	–	–
Long-Term Debt	1,262	1,036	922	745	398	–	–
Long-Term Leases	138	112	106	35	115	–	–
Operating Lease Liabilities	150	122	115	41	122	109	–
Deferred Tax Liabilities	7.87	1.81	0.05	0.31	0.15	–	–
Other Long-Term Liabilities	–	–	–	7.44	–	–	–
Total Liabilities	1,772	1,634	1,883	1,393	734	–	–
Total Debt	1,299	1,069	960	784	401	–	–
Common Stock	2.93	2.83	2.28	2.13	0.14	–	–
Additional Paid-In Capital	2,106	2,007	1,230	1,058	1,000	–	–
Retained Earnings	-2,410	-2,438	-2,206	-1,654	-1,141	–	–
Shareholders' Equity	–	–	–	-564	-136	–	–
Total Equity	-284	-413	-932	-564	-136	-867	-768
Total Liabilities & Equity	1,487	1,221	950	828	598	–	–
Shares Outstanding(shares)	312	302	267	252	0.89	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 59.8%
Operating margin: 13.3%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 1.65
Debt to equity: –
Debt to assets: 82.3%
Cash to current liabilities: 43.1%

Valuation

P/E ratio: 50.3
Price to sales: –
Price to book: –
Dividend yield: –